Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit
2020; Lippincott Williams & Wilkins; Volume: 13; Issue: 8 Linguagem: Inglês
10.1161/circep.120.008798
ISSN1941-3149
AutoresChristophe Beyls, Nicolas Martin, Alexis Hermida, Osama Abou‐Arab, Yazine Mahjoub,
Tópico(s)Pharmacological Receptor Mechanisms and Effects
ResumoHomeCirculation: Arrhythmia and ElectrophysiologyVol. 13, No. 8Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care UnitRisk of Bradycardia Christophe Beyls, Nicolas Martin, Alexis Hermida, Osama Abou-Arab and Yazine Mahjoub Christophe BeylsChristophe Beyls Correspondence to: Christophe Beyls, MD, Department of Anesthesiology and Critical Care Medicine, University Hospital Amiens, 1 Rond Point du Pr Cabrol, 80054 Amiens Cedex 1, France. Email E-mail Address: [email protected] https://orcid.org/0000-0001-8949-7348 Department of Anesthesiology and Critical Care Medicine (C.B., O.A.-A., Y.M.), Amiens University Hospital, France. , Nicolas MartinNicolas Martin Department of Rythmology (N.M., A.H.), Amiens University Hospital, France. , Alexis HermidaAlexis Hermida Department of Rythmology (N.M., A.H.), Amiens University Hospital, France. , Osama Abou-ArabOsama Abou-Arab https://orcid.org/0000-0003-3766-716X Department of Anesthesiology and Critical Care Medicine (C.B., O.A.-A., Y.M.), Amiens University Hospital, France. and Yazine MahjoubYazine Mahjoub Department of Anesthesiology and Critical Care Medicine (C.B., O.A.-A., Y.M.), Amiens University Hospital, France. Originally published9 Jul 2020https://doi.org/10.1161/CIRCEP.120.008798Circulation: Arrhythmia and Electrophysiology. 2020;13:e008798Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: July 9, 2020: Ahead of Print At the start of the coronavirus disease 2019 (COVID-19) outbreak in Europe, specific antiviral treatments were based on previous experience with SARS-Cov-1 (severe acute respiratory syndrome–coronavirus 1) and MERS-Cov (Middle East respiratory syndrome–related coronavirus) and on early experience with SARS-Cov-2 in China.1 One of the promising treatment was the combination of lopinavir (LPV) and ritonavir (RTV; Kaletra; Abbott Laboratories, Chicago, IL), previously used for the treatment of SARS-Cov-1 and MERS-CoV infections. LPV is a protease inhibitor of HIV-1 that is usually combined with RTV, another protease inhibitor that strongly inhibits hepatic CYP (cytochrome P450; CYP3A4) activity, to increase LPV plasma concentration and efficacy, with limited side effects.1,2 Separately, LPV is rapidly metabolized and has very low bioavailability.2 At the start of the outbreak, decision was made in our institution to treat COVID-19 critically ill patients with LPV/RTV. For HIV-1 patients, a risk of bradycardia was reported possibly due to nodal toxicity of LPV/RTV.3 To date, there are no data on bradycardia related to LPV/RTV treatment for COVID-19 critical ill patients. The aim of this prospective preliminary study was to record the risk of bradycardia for COVID-19 patients treated with LPV/RTV.During the first month of the outbreak, patients admitted in our intensive care unit with a positive real-time polymerase chain reaction for COVID-19 (on a nasopharyngeal swab) received LPV (200 mg)/RVT (50 mg) BID for 10 days. Bradycardia was defined as heart rate 24 hours. All patients were monitored 24 hours a day for all hemodynamic parameters including heart rate with 5-lead ECG. Monitors were linked to a computerized system allowing to extract hemodynamic data. LPV/RTV plasma concentration was monitored using an analytical method combining high-performance liquid chromatography and tandem mass spectrometry at 72 hours and every 72 hours. This was an ancillary study of a larger study evaluating the outcomes of critically ill COVID-19 patients (NCT04354558). Patients were divided into 2 groups according to the presence of bradycardia and then compared (Fisher exact or Mann-Whitney U test). A Spearman rank correlation between heart rate and plasma level of LPV/RTV was performed. The limit of statistical significance was P<0.05. All statistical analyses were performed with IBM SPSS software (SPSS, version 24; IBM, New York, NY). All data and supporting materials have been provided with the published article. Written informed consent was waived by the Amiens University Hospital IRB (Comite de Protection des Personnes Nord-Ouest II CHU, Place V. Pauchet, 80054 AMIENS Cedex 1).We prospectively included 41 COVID-19 patients who received LPV/RTV treatment. Nine (22%) patients experienced bradycardia (Table). No patient had preexisting nodal pathology on the ECG on admission. Among the 9 cases of bradycardia, 8 (88%) were sinus bradycardia and 1 (12%) third-degree atrioventricular block. Causality may be considered as bradycardia occurred at least 48 hours after LPV/RTV initiation, bradycardia resolved after discontinuation or dose reduction of LPV/RTV, and no alternative cause was found. Patients who presented with bradycardia were older (73 [62–80] versus 62 [54–68] years; P=0.009), had a higher RTV plasma concentration at 72 hours (1249 [820–1374] versus 652 [406–1176] ng·mL−1; P=0.036), and had a lower lymphocyte count (500 [265–105] versus 710 [600–800] 106·L−1; P=0.006). In our study, no correlation was found between RTV plasma concentration (r2=0.05, P=0.24), LPV plasma concentration (r2=0.01, P=0.98), and mean heart rate at day 3. No patient had bradycardia in the first 48 hours after LPV/RTV administration. For patients with LPV/RTV plasma level overdose, the dose of LPV/RTV was divided by 2 until the next dosage. For the patient with a third atrioventricular block, LPV/RTV was stopped. None of the patients had any known cytochrome CYP3A4-inhibiting drugs.Table. Comparison of Patients With and Without BradycardiaNo Bradycardia (n=32)Bradycardia (n=9)P ValueAge, y62 (54–68)73 (62–80)0.009*BMI, kg·m−230 (27–34)27 (25–34)0.273Male sex, n (%)21 (65)7 (77)0.39SOFA score at ICU admission6 (2–10)8 (4–12)0.31Chronic medication use, n (%) ACE inhibitors7 (21)3 (33)0.66 ARBs5 (15)3 (33)0.34 β-Blocker9 (28)2 (22)0.54 Diuretics10 (31)1 (11)0.22 Calcium blocker7 (21)2 (22)0.65Days from onset symptoms to LPV/RTV treatment8 (7–12)11 (7–16)0.23Days from beginning of LPV/RTV to bradycardia…6 (2–8)…ECG at ICU admission Heart rate, bpm88 (80–102)88 (77–92)0.69 P wave, ms80 (60–100)80 (60–100)0.95 PR, ms160 (152–180)160 (160–180)0.59 QRS, ms90 (80–95)95 (90–100)0.21 QTc, ms437 (420–460)410 (380–440)0.19Biological data PaO2/FiO2 ratio134 (80–157)117 (102–180)0.69 C-reactive protein, mg·L−1185 (63–298)158 (123–338)0.96 Procalcitonin, ug·L−10.21 (0.12–1.4)0.23 (0.14–1.2)0.93 Lymphocyte count×106 L−1710 (600–800)500 (265–1050)0.006* AST49 (37–82)41 (36–70)0.87 ALT34 (27–63)37 (21–57)0.89 aPTT70 (60–81)70 (69–79)0.72 HS C troponin, ng·mL141 (17–646)16 (8–55)0.37 BNP, pg·mL60 (35–160)33 (22–251)0.58Bradycardia characteristics on ECG Duration, h…48 (40–68)… Heart rate, bpm…46 (40–49)… Sinus bradycardia, n (%)…8… Third-degree AVB, n (%)…1… Serum potassium, mmol·L−1…4.3±0.7…Adjunctive therapy for bradycardia, n (%) Isoprenaline…1… Electrosystolic probe…1… Pacemaker…0… LPV/RTV dose reduction…4… LPV/RTV discontinuation…1…Drugs, n (%) Pantoprazole17 (53)3 (33)0.45 Propofol21 (65)5 (55)0.70 Midazolam6 (18)3 (33)0.38 Sufentanyl23 (71)9 (100)0.16 Vasopressors23 (72)8 (88)0.41Plasma level of RTV, ng/mL Day 3652 (406–1176)1249 (820–1374)0.036* Day 7539 (425–913)617 (344–1417)0.73Plasmatic level of LPV, ng/mL Day 314 900 (10 120–21 480)19 850 (14 960–21 945)0.49 Day 713 640 (690–15 760)16 350 (4211–24 240)0.14LPV/RTV duration, d6 (4–9)7 (6–9)0.38RTV cumulation dose, mg650 (350–925)900 (660–1150)0.09LPV cumulation dose, mg2600 (1400–3700)3600 (2650–4600)0.10Outcome Acute kidney injury7 (22)4 (44)0.381 RRT4 (58)4 (100)0.142 Mechanic ventilation23 (71)9 (100)0.16 Death6 (18)2 (22)1Data are expressed as mean±SD, median (interquartile range) or numbers (percentage). ACE indicates angiotensin-converting enzyme; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; ARB, angiotensin II receptor blocker; AST, aspartate aminotransferase; AVB, atrioventricular block; BMI, body mass index; BNP, B type natriuretic peptide; bpm, beats per minute; FiO2, fraction of inspired oxygen; HS, high sensitive; ICU, intensive care unit; LPV, lopinavir; RRT, renal replacement therapy; RTV, ritonavir; and SOFA, sepsis-related organ failure assessment.* Statistically significant (P<0.05).Our results suggest that RTV plasma overdose in elderly critical ill patients may increase the risk of bradycardia.In HIV-1 patients, cases of bradycardia-tachycardia syndrome and bradyarrythmia were reported, but the underlining pathophysiological mechanism remains unclear.3,4 Moreover, the use of LPV/RTV with drugs having an effect on the cardiovascular system could lead to bradycardia.5 In the LPV/RTV trial for suppression of SARS-COV-2 in China, Cao et al1 did not report any case of bradycardia. Compared with our study, their patients were less severe (only 15% on mechanical ventilation, no extracorporeal membrane oxygenation therapy) and younger (58 [50–68] years). Moreover, the majority of their patients did not have continuous heart rate monitoring during hospitalization, and no data on LPV/RTV plasmatic levels were reported.LPVs have complex pharmacokinetic characteristics, especially, concentration/dose nonlinearity that explains why concentration increase is not proportional to dose increase. RTV increases oral drug adsorption via inhibition of P-glycoprotein—a membrane transport protein of digestive tract, whose expression and functionality can be modulated by factors such as inflammatory state, genetic polymorphism, or age with significant consequences on drug exposition and interaction.6One hypothesis is that the inflammatory damage associated with COVID-19 increases intestinal absorption of RTV/LPV in elderly patients and increases the risk of bradycardia. The change in RTV/LPV doses administered and the decrease of inflammation during hospitalization could explain the regression of bradycardia. Nevertheless, bradycardia could be a sign of severe cardiological or neurological impairment since it is associated with lymphopenia that seems to reflect the severity of COVID-19 infection.Intensivists should be aware of this potential side effect to closely monitor LPV/RTV plasma levels notably in elderly patients.Sources of FundingNone.DisclosuresNone.FootnotesFor Sources of Funding and Disclosures, see page 864.Correspondence to: Christophe Beyls, MD, Department of Anesthesiology and Critical Care Medicine, University Hospital Amiens, 1 Rond Point du Pr Cabrol, 80054 Amiens Cedex 1, France. Email beyls.christophe@chu-amiens.frReferences1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19.N Engl J Med. 2020; 382:1787–1799. doi: 10.1056/NEJMoa2001282CrossrefMedlineGoogle Scholar2. Li F, Lu J, Ma X. CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.Drug Metab Dispos. 2012; 40:18–24. doi: 10.1124/dmd.111.041400CrossrefMedlineGoogle Scholar3. Kikuchi Y, Genka I, Ishizaki A, Sunagawa K, Yasuoka A, Oka S. Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome.Clin Infect Dis. 2002; 35:488–490. doi: 10.1086/341975CrossrefMedlineGoogle Scholar4. Yotsumoto M, Kitano K, Saito H. Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS.AIDS. 2005; 19:1547–1548. doi: 10.1097/01.aids.0000183942.05849.1bCrossrefMedlineGoogle Scholar5. Puech R, Gagnieu MC, Planus C, Charpiat B, Boibieux A, Ferry T, Tod M. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.Br J Clin Pharmacol. 2011; 71:621–623. doi: 10.1111/j.1365-2125.2010.03849.xCrossrefMedlineGoogle Scholar6. Fernandez C, Buyse M, German-Fattal M, Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality.J Pharm Pharm Sci. 2004; 7:359–371.MedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Cao H, Bu Q, Li Q, Yang L, Tang J and Yu G (2024) Evaluation of the DGT passive samplers for integrating fluctuating concentrations of pharmaceuticals in surface water, Science of The Total Environment, 10.1016/j.scitotenv.2024.172067, 926, (172067), Online publication date: 1-May-2024. Guerrero-Romero F, Micke O, Simental-Mendía L, Rodríguez-Morán M, Vormann J, Iotti S, Banjanin N, Rosanoff A, Baniasadi S, Pourdowlat G and Nechifor M (2023) Importance of Magnesium Status in COVID-19, Biology, 10.3390/biology12050735, 12:5, (735) DeMarco E, Turnipseed M, Clarke B and Qadeer F (2023) Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19, SAGE Open Medical Case Reports, 10.1177/2050313X231168304, 11, (2050313X2311683), Online publication date: 1-Jan-2023. Chang X, Ismail N, Rahman A, Xu D, Chan R, Ong S and Ong S (2022) Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?, Antioxidants & Redox Signaling, 10.1089/ars.2022.0126 Jakobi T, Groß J, Cyganek L and Doroudgar S (2022) Transcriptional Effects of Candidate COVID-19 Treatments on Cardiac Myocytes, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.844441, 9 Mohapatra S, Ananda P and Tripathy S (2022) Pharmacological consideration of COVID-19 infection and vaccines in pregnancy, Journal of the Chinese Medical Association, 10.1097/JCMA.0000000000000712, 85:5, (537-542), Online publication date: 1-May-2022. Varnasseri M, Siahpoosh A, Hoseinynejad K, Amini F, Karamian M, Yad M, Cheraghian B and Khosravi A (2022) The effects of add-on therapy of Phyllanthus Emblica (Amla) on laboratory confirmed COVID-19 Cases: A randomized, double-blind, controlled trial, Complementary Therapies in Medicine, 10.1016/j.ctim.2022.102808, 65, (102808), Online publication date: 1-May-2022. Kewedar S and Abulamoun K (2022) The Effects of Coronavirus on Human Health and Their Influence on Other Aspects of Life: A Scoping Review, Biosciences Biotechnology Research Asia, 10.13005/bbra/2967, 19:1, (47-68), Online publication date: 31-Mar-2022. Nappi F, Iervolino A and Avtaar Singh S (2022) Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes, Biomedicines, 10.3390/biomedicines10020437, 10:2, (437) Lima N, Fernandes B, Alves G, de Souza J, Siqueira M, Patrícia do Nascimento M, Moreira O, Sussulini A and de Oliveira M (2022) Mass spectrometry applied to diagnosis, prognosis, and therapeutic targets identification for the novel coronavirus SARS-CoV-2: A review, Analytica Chimica Acta, 10.1016/j.aca.2021.339385, 1195, (339385), Online publication date: 1-Feb-2022. Zurdinova A and Kutmanova A (2021) Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan, Safety and Risk of Pharmacotherapy, 10.30895/2312-7821-2021-9-4-191-199, 9:4, (191-199) Santos J, Zanardi P, Alo V, Rodriguez M, Magdaleno F, De Langhe V, Dos Santos V, Murialdo G, Villoldo A, Coria M, Quiros D, Milicchio C and Garcia Saiz E (2021) Pulmonary Edema in COVID-19 Treated with Furosemide and Negative Fluid Balance (NEGBAL): A Different and Promising Approach, Journal of Clinical Medicine, 10.3390/jcm10235599, 10:23, (5599) Davis J, Umeh U and Saba R (2021) Treatment of SARS-CoV-2 (COVID-19): A safety perspective, World Journal of Pharmacology, 10.5497/wjp.v10.i1.1, 10:1, (1-32), Online publication date: 20-Nov-2021. Nassar Y, Mokhtar A, Elhadidy A, Elsayed M, Mostafa F, Rady A, Eladawy A, Elshazly M, Saeed M, Mokhtar S, Buschbeck S and Sakr Y (2021) Outcomes and risk factors for death in patients with coronavirus disease-2019 (COVID-19) pneumonia admitted to the intensive care units of an Egyptian University Hospital. A retrospective cohort study, Journal of Infection and Public Health, 10.1016/j.jiph.2021.06.012, 14:10, (1381-1388), Online publication date: 1-Oct-2021. Stancampiano F, Omer M, Harris D, Valery J, Heckman M, White L and Libertin C (2021) Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 Pneumonia Who Developed Bradycardia, Southern Medical Journal, 10.14423/SMJ.0000000000001269, 114:7, (432-437), Online publication date: 1-Jul-2021. Diaz‐Arocutipa C, Brañez‐Condorena A and Hernandez A (2021) QTc prolongation in COVID ‐19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta‐analysis , Pharmacoepidemiology and Drug Safety, 10.1002/pds.5234, 30:6, (694-706), Online publication date: 1-Jun-2021. Hallberg T, Bjorklund A, Slusher T and Rodgers N (2021) Sinus bradycardia in a toddler with multisystem inflammatory syndrome in children (MIS-C) related to COVID-19, BMJ Case Reports, 10.1136/bcr-2021-242058, 14:5, (e242058), Online publication date: 1-May-2021. Indari O, Jakhmola S, Manivannan E and Jha H (2021) An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?, Frontiers in Pharmacology, 10.3389/fphar.2021.632677, 12 Ibrahim Fouad G (2021) A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19), Bulletin of the National Research Centre, 10.1186/s42269-021-00487-0, 45:1 Magro P, Zanella I, Pescarolo M, Castelli F and Quiros-Roldan E (2021) Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment, Biomedical Journal, 10.1016/j.bj.2020.11.005, 44:1, (43-53), Online publication date: 1-Feb-2021. Mante P, Adomako N, Omuojine J and Antwi P (2021) Pharmacological management of seizures in patients with COVID-19: a systematic review, Open Research Africa, 10.12688/aasopenres.13224.2, 4, (29) Mante P, Adomako N, Omuojine J and Antwi P (2021) Pharmacological management of seizures in patients with COVID-19: a systematic review, AAS Open Research, 10.12688/aasopenres.13224.1, 4, (29) (2020) Lopinavir/ritonavir, Reactions Weekly, 10.1007/s40278-020-83542-y, 1822:1, (189-189), Online publication date: 1-Sep-2020. (2020) Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients, Reactions Weekly, 10.1007/s40278-020-80996-7, 1814:1, (9-9), Online publication date: 1-Jul-2020. August 2020Vol 13, Issue 8 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCEP.120.008798PMID: 32809882 Originally publishedJuly 9, 2020 KeywordsbradycardiaCOVID-19critical illnesshumanslopinavirritonavirPDF download Advertisement SubjectsComplicationsPharmacology
Referência(s)